The Quality by Design (QbD) term was originally introduced in the pharmaceutical lexicon in 2005 via ICH Q8(R2) and additionally described in ICH Q9 and Q10.  In essence, QbD is a systematic risk management approach which emphasizes maximum product-, process-understanding, and process control in contrast to a trial and error-based quality control approach that banks on success primarily via end stage product testing. 
Amidst the global pandemic, there was an urgent need to manufacture Covid vaccines across the globe. In this scenario, the pharma company Catalent converted one of its aseptic processing lines, which specialized in powder processing, to liquid processing. The move helped the firm to produce its first commercial batch of Covid vaccines in April 2021.
The Covid-19 pandemic is far from over, and the threat of future pandemics created by novel viruses is very real. There is a growing need to supply a global market with innovative medicines at a profitable cost. So pharmaceutical equipment manufacturers have to react quickly, while maintaining due levels of diligence and social responsibility. To meet this demand, we at Ima Group operate in highly specialized pharmaceutical divisions, focusing on specific processing and packaging areas, in order to provide our customers real added value based on two main criteria.
Ima Group gave life to a wide number of technologies and platforms dedicated to production monitoring and efficiency increase. In particular, it is worth mentioning about A4gate which is specifically created to tackle cyber-attacks, Ima Sentinel for remote production monitoring 24/7 and Ima Control Room for more sophisticated services.
The pharmaceutical industry is facing enormous challenges. In an exclusive video interview with PROCESS Worldwide, Fabriano Ferrini, Product Manager for Tablet Presses at Ima Active, shares the hurdles faced by suppliers of tablet presses in the pharma sector as well as informs us about the company’s Domina online event which will introduce a new configurable platform for tablet manufacturing.
Laphal Industries purchased Prexima 300, a middle-size industrial tablet press from Ima and explored the reliability and flexibility of the machine. The company was also able to find out the best process parameters according to its requirements.
If you are keen on upgrading your capsule filling machine, read this space. With the global capsule filling machines market predicted to reach 440 million dollars by 2025, many new interesting features including dosing precision, in-line control of critical quality and handling of difficult products have been enhanced in these machines.
Continuous manufacturing is nowadays one of the main drivers of innovation in the pharmaceutical industry. Strongly encouraged by the regulatory authorities for drug production, continuous manufacturing can ensure flexible and efficient production, while improving the pharmaceutical products in terms of potency, effectiveness and safety.